X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Princess Volume Plus (hyaluronic acid) dermal filler and Lidocaine with the intention to confirm the efficacy and safety in respect of mid-facial volume insufficiency and/or mid-facial profile deficient participants.
Lead Product(s): Hyaluronic Acid,Lidocaine
Therapeutic Area: Dermatology Product Name: Princess Volume Plus
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023
Details:
Croma will promote Pliaglis directly to physicians through its sales network consisting of approximately 130 members across the Territories. As part of the agreement, Crescita is eligible to receive a combination of upfront, cumulative sales and other milestone payments.
Lead Product(s): Lidocaine,Tetracaine
Therapeutic Area: Neurology Product Name: Pliaglis
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Crescita Therapeutics
Deal Size: $1.4 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 28, 2021
Details:
The joint venture comprises Croma's Hyaluronic Acid Filler Princess® VOLUME and additional filler and facial aesthetic products and CNBG's multi-channel distribution, marketing experience and synergistic products, specifically its botulinum toxin product Heng Li®.
Lead Product(s): Hyaluronic Acid
Therapeutic Area: Dermatology Product Name: Hyaluronic Acid Filler Princess
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: China National Biotech Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 15, 2020
Details:
Croma’s botulinum toxin submission in Europe is based on 2 completed randomized, placebo-controlled Phase III pivotal trials (BLESS I and II) that enrolled a total of 917 subjects in Europe and the US.
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Dermatology Product Name: BoNT/A-DP
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
